A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Authors :: Lanza F
Saraceni F
Pezzi A
Martino M
Bosi A
Cascavilla N
Musto P
Zuffa E
Tani M
Cellini C
Laszlo D
Bonifazi F
Source :: American journal of hematology [Am J Hematol] 2017 Sep; Vol. 92 (9), pp. E557-E559. Date of Electronic Publication: 2017 Jul 24.
Publication Year :: 2017

Subjects :: Benzylamines
Biosimilar Pharmaceuticals administration & dosage
Blood Cell Count
Cyclams
Filgrastim administration & dosage
Heterocyclic Compounds administration & dosage
Humans
Lymphoma, Non-Hodgkin blood
Multiple Myeloma blood
Propensity Score
Retrospective Studies
Biosimilar Pharmaceuticals pharmacology
Filgrastim pharmacology
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds pharmacology
Lymphoma, Non-Hodgkin therapy
Multiple Myeloma therapy

Full Text Access

Tools